Iron and Genetics: How Your Genes Influence Iron Absorption and Anemia Risk

Iron is the most abundant mineral in the human body after calcium — and one of the most critical for life. It sits at the heart of hemoglobin, the protein that carries oxygen from the lungs to every cell in the body; it is a cofactor for hundreds of enzymes; and it is essential for DNA synthesis, mitochondrial energy production, and immune system function. Despite its fundamental importance, iron deficiency is the most prevalent nutritional deficiency in the world, affecting more than 2 billion people. At the same time, hereditary hemochromatosis — the pathological accumulation of iron — is the most common genetic disease among populations of European ancestry.

Here is what many people don't know: two individuals can follow nearly identical diets in iron content, yet one may develop severe iron-deficiency anemia while the other accumulates iron in their organs to the point of causing hepatic cirrhosis and heart failure. The explanation is not on the plate — it is in the DNA. Variants in the genes HFE, TMPRSS6, SLC11A2, TFR2, and other iron metabolism regulators largely determine how much iron you absorb, how you distribute it, and how efficiently you recycle it. Understanding your iron genetics can make the difference between a nutritional strategy that works and years of misdirected supplementation.

The Biology of Iron: From Diet to Cell

Before exploring the genetics, it is essential to understand iron's journey through the body. Dietary iron exists in two main forms: heme iron, derived from animal proteins such as red meat and organ meats, and non-heme iron, found in vegetables, legumes, and grains. Heme iron is absorbed directly by the enterocyte (the small intestinal cell) with an efficiency of 15 to 35%. Non-heme iron — the predominant form in diets of populations with low meat consumption — first requires reduction from Fe³⁺ (ferric) to Fe²⁺ (ferrous) by the enzyme duodenal cytochrome b reductase (DCYTB), and can then be internalized by the DMT1 transporter (encoded by the SLC11A2 gene), with much lower efficiency — only 2 to 10%.

Once inside the enterocyte, iron has two possible fates: it can be stored as ferritin (and lost when the intestinal cell sloughs off after a few days) or exported into the bloodstream by ferroportin (gene SLC40A1). The amount exported is regulated by a liver hormone called hepcidin (gene HAMP): when iron stores are elevated or inflammation is present, the liver increases hepcidin production, which binds to ferroportin and degrades it, blocking iron export. When stores are low, hepcidin falls, ferroportin remains active, and more iron enters circulation.

It is within this regulatory axis — intestinal absorption, hepatic signaling via hepcidin, and systemic transport — that the major iron metabolism genes operate. Variants in these pathways shift the system's "set point," determining whether you chronically tend to absorb too little or too much iron.

The Iron Genes: Mechanisms and Scientific Evidence

HFE — The Hereditary Hemochromatosis Gene

The HFE gene (located on chromosome 6p21.3) encodes an atypical HLA class I protein that regulates iron uptake by hepatocytes through interaction with transferrin receptor 1 (TFR1). Mutations in HFE were identified by Feder et al. in 1996 (Nature Genetics) as the cause of hereditary hemochromatosis type 1, the most prevalent autosomal recessive genetic disease in Europeans. The two most functionally relevant variants are:

• C282Y (rs1800562): A cysteine-to-tyrosine substitution at position 282. In homozygosity, it prevents the HFE protein from binding to TFR1 and consequently disrupts the signaling for hepcidin production. The result is dysregulated absorption and progressive accumulation of iron in the liver, heart, pancreas, and joints. Present in ~5–10% of individuals of northern European ancestry as heterozygotes; homozygosity occurs in approximately 1:200–1:400.
• H63D (rs1799945): A histidine-to-aspartate substitution at position 63. Produces a more moderate effect; compound heterozygosity with C282Y can cause mild iron overload in some individuals.

Heterozygous carriers for C282Y tend to have slightly higher ferritin levels and transferrin saturation than the general population — which can be clinically relevant in contexts of high iron intake or unnecessary supplementation. A large-scale UK Biobank study with more than 150,000 participants (Pilling et al., PLOS Medicine, 2019) showed that C282Y/C282Y homozygotes had an odds ratio of 7.9 for hemochromatosis diagnosis and elevated risks for cirrhosis (OR 4.5), arthropathy (OR 2.6), and diabetes (OR 2.2).

TMPRSS6 — The Gene Behind Refractory Iron-Deficiency Anemia

If HFE is the iron overload gene, TMPRSS6 is, in many respects, the gene of the most common and underdiagnosed genetic anemia. This gene encodes matriptase-2, a transmembrane serine protease expressed in the liver that cleaves the hepcidin co-receptor (HJV/hemojuvelin), suppressing hepcidin production and thereby promoting iron absorption.

Biallelic mutations in TMPRSS6 cause Iron-Refractory Iron Deficiency Anemia (IRIDA), a condition in which hepcidin levels remain inappropriately elevated even with depleted iron stores, blocking intestinal absorption and iron mobilization from macrophages. IRIDA patients present with severe microcytosis, hypochromia, and very low serum iron, but do not respond to oral iron — only to intravenous iron, which bypasses the intestinal blockade.

Beyond the rare mutations that cause IRIDA, common variants in TMPRSS6 — especially rs855791 (A736V) — have been repeatedly identified in GWAS as the strongest genetic determinants of hemoglobin levels and mean corpuscular volume in the general population. A GWAS meta-analysis with more than 130,000 individuals (Benyamin et al., Nature Genetics, 2009) identified the TMPRSS6 locus as most significantly associated with variation in erythrocyte parameters in Europeans. The A736V allele reduces matriptase-2 activity, slightly increases hepcidin, and decreases iron absorption — an effect particularly relevant for women of childbearing age with heavy menstrual losses.

SLC11A2 (DMT1) — The Enterocyte Iron Transporter

The SLC11A2 gene encodes divalent metal transporter 1 (DMT1), the protein responsible for capturing non-heme ferrous iron (Fe²⁺) from the intestinal lumen into the enterocyte. Rare mutations in SLC11A2 cause congenital microcytic anemia with hepatic iron overload — a paradoxical phenotype explained by the fact that when intestinal DMT1 is deficient, the body attempts to compensate by increasing transferrin production and TFR1-mediated absorption in hepatocytes, which express a different isoform of DMT1.

More relevant to the general population are common SLC11A2 variants that alter transporter expression. A promoter region polymorphism (rs224589) has been associated with greater susceptibility to iron-deficiency anemia in Brazilian and Asian population studies, with an effect more pronounced in populations whose diet is predominantly non-heme iron-based (vegetarian or with low red meat consumption).

TFR2 — The Hepatic Iron Sensor

The TFR2 gene (transferrin receptor 2) encodes a protein that acts as a sensor of circulating iron levels in hepatocytes. When plasma transferrin is iron-saturated, TFR2 interacts with HFE and stimulates hepcidin production. Mutations in TFR2 cause hemochromatosis type 3, phenotypically similar to HFE-related hemochromatosis but with earlier onset.

GWAS studies have identified common TFR2 variants associated with serum ferritin levels in the general population. A study with more than 48,000 European participants (Benyamin et al., Human Molecular Genetics, 2011) showed that the TFR2-HFE locus is the second largest genetic determinant of ferritin levels after HFE itself, with variants that influence hepatic sensitivity to the iron signal and the consequent calibration of hepcidin.

Comparative Overview: Key Genes in Iron Metabolism

Why the Same Ferritin Level Means Different Things for Different People

One of the most important practical consequences of iron genetics is that laboratory reference ranges are population-level averages, not individual benchmarks. A ferritin level of 15 ng/mL (at the lower end of "normal") in a heterozygous C282Y carrier means something completely different from that same value in a woman with a TMPRSS6 risk variant.

In the first case, the body may be efficiently conserving iron with stores relatively adequate for that genetic profile. In the second case, the woman may have functionally depleted stores, with subclinical deficiency impacting neurotransmitter production (serotonin, dopamine), thyroid function, mitochondrial muscle efficiency, and immune response — yet the lab report will simply read "within normal limits."

Functional studies in TMPRSS6 knockout mice under dietary iron deprivation conditions demonstrated that these animals develop cognitive impairment and chronic fatigue even with hemoglobin levels still within the normal range — evidence that functional deficiency precedes laboratory anemia in genetic profiles characterized by low absorption.

Gene-Nutrient Interactions: When Diet Meets DNA

Iron genetics does not operate in a vacuum — it interacts in complex ways with dietary factors that can amplify or attenuate the effects of genetic variants:

• Vitamin C: Reduces Fe³⁺ to Fe²⁺ in the intestinal lumen, increasing non-heme iron absorption. For carriers of low-absorption variants in SLC11A2 or TMPRSS6, this strategy can be particularly effective — consuming vitamin C sources alongside non-heme iron-rich foods can partially compensate for the functional transporter deficiency.
• Phytates and tannins: These chelate iron in the gut, drastically reducing absorption. For carriers of low-absorption variants, a diet rich in legumes, whole grains, and tea without mitigation strategies (such as soaking legumes before cooking) can be clinically problematic.
• Calcium: Competes with iron for DMT1. In carriers of SLC11A2 variants, taking iron and calcium supplements simultaneously can negate the benefits of the iron.
• Alcohol: Increases iron absorption and reduces the liver's ability to produce hepcidin. In heterozygous or homozygous C282Y carriers, regular alcohol consumption dramatically accelerates iron accumulation in organs.

Practical Implications: What to Do With This Information

Knowledge of your iron metabolism genetic profile enables far more precise strategies than generic population-level recommendations. Some practical implications include:

• Carriers of high-risk HFE variants (C282Y/C282Y or C282Y/H63D): Should avoid iron supplementation without clear medical indication, reduce red meat and alcohol consumption, and regularly monitor ferritin and transferrin saturation. In confirmed cases of hemochromatosis, therapeutic phlebotomy is the gold-standard treatment.
• Carriers of low-absorption variants in TMPRSS6 or SLC11A2: Should prefer heme iron (lean red meats, organ meats) over non-heme iron, consume vitamin C with meals, avoid coffee, tea, and calcium alongside iron-rich foods, and consider more frequent ferritin monitoring — especially women of childbearing age, pregnant women, and athletes.
• All carriers of risk variants: Should communicate their genetic profile to their physician before any supplementation, as indiscriminate iron supplementation can be harmful in carriers of accumulation variants — and ineffective without dietary adjustments in carriers of malabsorption variants.

What helixXY Can Reveal

The helixXY genetic report includes analysis of the most clinically relevant variants in iron metabolism, based on high-quality scientific evidence. For the nutrition and mineral metabolism profile, helixXY analyzes:

• Functional variants in the HFE gene (C282Y, H63D, S65C) and their risk classification for hereditary hemochromatosis;
• The rs855791 (A736V) polymorphism in the TMPRSS6 gene, associated with variation in erythrocyte parameters and iron-deficiency anemia risk;
• Variants in SLC11A2 that influence intestinal non-heme iron absorption — especially relevant for vegetarians, vegans, and plant-based diet populations;
• Variants in TFR2 associated with hepatic hepcidin calibration and the individual ferritin profile.

Based on your specific genetic profile, helixXY reports offer personalized recommendations about the best dietary iron sources for your profile, nutritional interactions to consider, and priority laboratory parameters for ongoing monitoring. Precision nutrition based on genetics goes beyond daily recommended intake tables — it starts from the principle that your DNA defines your starting point, and that optimizing health requires respecting that biological individuality.

Important: helixXY reports are informational and educational. Consult a healthcare professional — physician or registered dietitian — for clinical interpretation of results and therapeutic decisions.

References

• Feder JN et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nature Genetics. 1996;13(4):399–408.
• Benyamin B et al. Common variants in TMPRSS6 are associated with iron status and erythrocyte volume. Nature Genetics. 2009;41(11):1173–1175.
• Finberg KE et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nature Genetics. 2008;40(5):569–571.
• Pilling LC et al. Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank. PLOS Medicine. 2019;16(1):e1002746.
• World Health Organization. Nutritional anaemias: tools for effective prevention and control. Geneva: WHO; 2017.